ATE298765T1 - Beta-amyloid peptidaggregation regulierende peptide mit d-aminosäuren - Google Patents
Beta-amyloid peptidaggregation regulierende peptide mit d-aminosäurenInfo
- Publication number
- ATE298765T1 ATE298765T1 AT97940663T AT97940663T ATE298765T1 AT E298765 T1 ATE298765 T1 AT E298765T1 AT 97940663 T AT97940663 T AT 97940663T AT 97940663 T AT97940663 T AT 97940663T AT E298765 T1 ATE298765 T1 AT E298765T1
- Authority
- AT
- Austria
- Prior art keywords
- beta
- peptide
- amyloid peptide
- compounds
- amino
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 150000008574 D-amino acids Chemical class 0.000 title abstract 4
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title abstract 4
- 230000006919 peptide aggregation Effects 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
- 125000003368 amide group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 abstract 1
- 229930182819 D-leucine Natural products 0.000 abstract 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 abstract 1
- 229930182832 D-phenylalanine Natural products 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000003367 polycyclic group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/703,675 US6303567B1 (en) | 1995-03-14 | 1996-08-27 | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
| US89734297A | 1997-07-21 | 1997-07-21 | |
| PCT/US1997/015166 WO1998008868A1 (en) | 1996-08-27 | 1997-08-27 | MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE298765T1 true ATE298765T1 (de) | 2005-07-15 |
Family
ID=27107183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97940663T ATE298765T1 (de) | 1996-08-27 | 1997-08-27 | Beta-amyloid peptidaggregation regulierende peptide mit d-aminosäuren |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP0929574B1 (de) |
| JP (1) | JP2001500852A (de) |
| AT (1) | ATE298765T1 (de) |
| AU (1) | AU741199B2 (de) |
| CA (1) | CA2262453A1 (de) |
| DE (1) | DE69733655T2 (de) |
| DK (1) | DK0929574T3 (de) |
| ES (1) | ES2245003T3 (de) |
| PT (1) | PT929574E (de) |
| WO (1) | WO1998008868A1 (de) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277826B1 (en) | 1996-08-27 | 2001-08-21 | Praecis Pharmaceuticals, Inc. | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
| US5985242A (en) * | 1995-10-27 | 1999-11-16 | Praecis Pharmaceuticals, Inc. | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
| EP0866805A1 (de) | 1995-12-12 | 1998-09-30 | Karolinska Innovations AB | Peptide, das die KLVFF Sequenz von beta-Amyloid bindet |
| US6172043B1 (en) * | 1997-01-10 | 2001-01-09 | Massachusetts Institute Of Technology | Treatments for neurotoxicity in Alzheimer's disease caused by β amyloid peptides |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| ES2290023T3 (es) | 1999-03-04 | 2008-02-16 | Praecis Pharmaceuticals Incorporated | Moduladores de la agregacion del peptido beta-amiloide que comprenden d-aminoacidos. |
| EP1870419A3 (de) * | 1999-03-04 | 2008-01-02 | Praecis Pharmaceuticals Incorporated | Modulatoren der Beta-Amyloid-Peptid-Aggregation mit D-Aminosäuren |
| US7060670B1 (en) | 1999-05-05 | 2006-06-13 | Neurochem (International) Limited | Stereoselective antifibrillogenic peptides and peptidomimetics thereof |
| ATE384077T1 (de) * | 1999-05-05 | 2008-02-15 | Neurochem Int Ltd | Stereoselektive antifibrillogene peptide |
| JP2004513873A (ja) * | 1999-11-05 | 2004-05-13 | アクソニックス，インコーポレイティド | アミロイド、アミロイド様沈着物またはそれらのβ−シートリッチな病理前駆体への異常タンパク質折り畳みに関係する疾患の治療における生体内使用に適するペプチド類似物および模倣物 |
| NZ540564A (en) * | 1999-11-29 | 2007-04-27 | Neurochem Int Ltd | Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases |
| CA2398567A1 (en) * | 2000-02-11 | 2001-08-16 | Praecis Pharmaceuticals Incorporated | Methods for enhancing the bioavailability of a drug |
| GB2363983A (en) | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 7-hydroxyepiandrosterone |
| GB2363984A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids |
| WO2002035987A2 (en) | 2000-11-03 | 2002-05-10 | Massachusetts Institute Of Technology | METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY β-AMYLOID PEPTIDES |
| US7067550B2 (en) | 2000-11-03 | 2006-06-27 | Massachusetts Institute Of Technology | Treatments for neurotoxicity in Alzheimer's Disease |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| CA2434831C (en) * | 2001-01-17 | 2012-03-06 | Robert H. Zimmer | Polypeptide drug substances |
| JP4354180B2 (ja) * | 2001-12-26 | 2009-10-28 | 武田薬品工業株式会社 | 軽度認知障害治療剤 |
| US20040052928A1 (en) | 2002-09-06 | 2004-03-18 | Ehud Gazit | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
| PL371366A1 (en) | 2002-03-01 | 2005-06-13 | Takeda Pharmaceutical Company Limited | Antidepressant |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| US6846640B2 (en) | 2002-04-30 | 2005-01-25 | Pharmacia & Upjohn Company | Time-resolved fluorescence assay for the detection of multimeric forms of A-beta 1-40 |
| PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
| CN101415724B (zh) | 2003-06-30 | 2015-12-02 | 特拉维夫大学未来科技开发有限公司 | 肽、抗肽抗体以及用它们来诊断和治疗淀粉样蛋白相关疾病的方法 |
| ES2396555T3 (es) | 2004-12-15 | 2013-02-22 | Janssen Alzheimer Immunotherapy | Anticuerpos que reconocen péptido beta amiloide |
| PE20061329A1 (es) | 2004-12-15 | 2006-12-08 | Neuralab Ltd | Anticuerpos ab humanizados para mejorar la cognicion |
| EP1923388A4 (de) | 2005-08-12 | 2011-03-09 | Takeda Pharmaceutical | Gehirn-/nervenzellenschutzmittel und therapeutikum für schlafstörungen |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| EP2089419A2 (de) * | 2006-10-27 | 2009-08-19 | Zapaloid Limited | Inhibierung der beta-amyloid-aggregation |
| US7713937B2 (en) | 2006-11-10 | 2010-05-11 | Cara Therapeutics, Inc. | Synthetic peptide amides and dimeric forms thereof |
| US7842662B2 (en) | 2006-11-10 | 2010-11-30 | Cara Therapeutics, Inc. | Synthetic peptide amide dimers |
| US8236766B2 (en) | 2006-11-10 | 2012-08-07 | Cara Therapeutics, Inc. | Uses of synthetic peptide amides |
| PL2064228T3 (pl) | 2006-11-10 | 2013-01-31 | Cara Therapeutics Inc | Syntetyczne amidy peptydowe |
| US8906859B2 (en) | 2006-11-10 | 2014-12-09 | Cera Therapeutics, Inc. | Uses of kappa opioid synthetic peptide amides |
| EP2121633A2 (de) | 2007-02-12 | 2009-11-25 | Merck & Co., Inc. | Piperazinderivate zur behandlung von alzheimer-krankheit und verwandten leiden |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| SI2182983T1 (sl) | 2007-07-27 | 2014-09-30 | Janssen Alzheimer Immunotherapy | Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| WO2010104194A1 (en) | 2009-03-10 | 2010-09-16 | Takeda Pharmaceutical Company Limited | Benzofuran derivatives |
| CA2813911A1 (en) | 2010-10-07 | 2012-04-12 | Takeda Pharmaceutical Company Limited | 1,4-oxazepane derivatives |
| BR112013012033A2 (pt) | 2010-11-15 | 2016-08-09 | Merz Pharma Gmbh & Co Kgaa | análogos de dipeptídeos para o tratamento de condições associadas com a formação de fibrila amiloide |
| CA2851087C (en) | 2011-10-07 | 2019-09-24 | Takeda Pharmaceutical Company Limited | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases |
| WO2014061676A1 (ja) | 2012-10-16 | 2014-04-24 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2014092100A1 (ja) | 2012-12-11 | 2014-06-19 | 武田薬品工業株式会社 | 複素環化合物 |
| US9598398B2 (en) | 2013-04-04 | 2017-03-21 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP2982670B1 (de) | 2013-04-04 | 2018-11-07 | Takeda Pharmaceutical Company Limited | Heterocyclische verbindung |
| JP6533799B2 (ja) | 2014-06-09 | 2019-06-19 | 武田薬品工業株式会社 | 放射標識された化合物 |
| EP4438041A3 (de) | 2016-02-04 | 2025-01-01 | Takeda Pharmaceutical Company Limited | Substituierte piperidinverbindung und verwendung davon |
| EP3594203B1 (de) | 2017-03-08 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Substituierte pyrrolidinverbindung und verwendung davon |
| WO2019022179A1 (ja) | 2017-07-28 | 2019-01-31 | 武田薬品工業株式会社 | 複素環化合物 |
| JP6574918B1 (ja) | 2017-08-03 | 2019-09-11 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| JP7279067B2 (ja) | 2018-03-28 | 2023-05-22 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| EP3816154B1 (de) | 2018-06-29 | 2025-04-23 | Takeda Pharmaceutical Company Limited | Heterocyclische verbindung und anwendung davon |
| MA54823A (fr) | 2019-01-24 | 2022-04-27 | Takeda Pharmaceuticals Co | Composé hétérocyclique et son utilisation |
| TWI855081B (zh) | 2019-05-24 | 2024-09-11 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| KR20220062361A (ko) | 2019-09-13 | 2022-05-16 | 다케다 야쿠힌 고교 가부시키가이샤 | 과도한 졸림의 치료를 위한 오렉신 2 수용체 효능제의 용도 |
| US20220339143A1 (en) | 2019-09-13 | 2022-10-27 | Takeda Pharmaceutical Company Limited | Tak-925 for use in treating narcolepsy |
| JP2021050161A (ja) | 2019-09-25 | 2021-04-01 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| JP2021080177A (ja) | 2019-11-14 | 2021-05-27 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| WO2021106975A1 (ja) | 2019-11-27 | 2021-06-03 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2021183587A (ja) | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
| IL303170A (en) | 2020-11-25 | 2023-07-01 | Sage Therapeutics Inc | 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders |
| AR125073A1 (es) | 2021-03-12 | 2023-06-07 | Takeda Pharmaceuticals Co | Uso de un agonista del receptor de orexina 2 para el tratamiento de una enfermedad o trastorno mediados por orexina |
| TW202304437A (zh) | 2021-04-02 | 2023-02-01 | 日商武田藥品工業股份有限公司 | 食慾激素２受體促效劑對於手術後復原的用途 |
| US20250145947A1 (en) | 2021-11-17 | 2025-05-08 | Takeda Pharmaceutical Company Limited | Cell production method |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5338837A (en) * | 1991-12-13 | 1994-08-16 | The Trustees Of Princeton University | Glycosylated steroid derivatives for transport across biological membranes and process for making same |
| WO1994019692A1 (en) * | 1993-02-18 | 1994-09-01 | The General Hospital Corporation | Alzheimer's disease therapeutics |
| US5854204A (en) * | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals, Inc. | Aβ peptides that modulate β-amyloid aggregation |
| EP0866805A1 (de) * | 1995-12-12 | 1998-09-30 | Karolinska Innovations AB | Peptide, das die KLVFF Sequenz von beta-Amyloid bindet |
-
1997
- 1997-08-27 CA CA002262453A patent/CA2262453A1/en not_active Abandoned
- 1997-08-27 DE DE69733655T patent/DE69733655T2/de not_active Expired - Fee Related
- 1997-08-27 EP EP97940663A patent/EP0929574B1/de not_active Expired - Lifetime
- 1997-08-27 WO PCT/US1997/015166 patent/WO1998008868A1/en not_active Ceased
- 1997-08-27 AT AT97940663T patent/ATE298765T1/de not_active IP Right Cessation
- 1997-08-27 JP JP10511914A patent/JP2001500852A/ja not_active Ceased
- 1997-08-27 EP EP05013789A patent/EP1586584A1/de not_active Withdrawn
- 1997-08-27 AU AU42387/97A patent/AU741199B2/en not_active Ceased
- 1997-08-27 DK DK97940663T patent/DK0929574T3/da active
- 1997-08-27 ES ES97940663T patent/ES2245003T3/es not_active Expired - Lifetime
- 1997-08-27 PT PT97940663T patent/PT929574E/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU741199B2 (en) | 2001-11-22 |
| ES2245003T3 (es) | 2005-12-16 |
| DK0929574T3 (da) | 2005-10-31 |
| AU4238797A (en) | 1998-03-19 |
| PT929574E (pt) | 2005-11-30 |
| DE69733655D1 (de) | 2005-08-04 |
| HK1021741A1 (en) | 2000-06-30 |
| WO1998008868A1 (en) | 1998-03-05 |
| DE69733655T2 (de) | 2006-04-27 |
| EP0929574B1 (de) | 2005-06-29 |
| EP1586584A1 (de) | 2005-10-19 |
| EP0929574A1 (de) | 1999-07-21 |
| CA2262453A1 (en) | 1998-03-05 |
| JP2001500852A (ja) | 2001-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69733655D1 (de) | beta-AMYLOID PEPTIDAGGREGATION REGULIERENDE PEPTIDE MIT D-AMINOSÄUREN | |
| ATE366259T1 (de) | Beta-amyloid-peptidaggregation regulierende peptide mit d-aminosäuren | |
| DE69739035D1 (de) | Zusammensetzungen und Methoden zur Behandlung von Infektionen unter Verwendung von Indolicidinanalogen | |
| DE69129865D1 (de) | Osteogene peptide | |
| DK0792287T3 (da) | Peptidanaloger af humant basisk myelinprotein | |
| DE60041119D1 (de) | Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen | |
| NO920671L (no) | Fremgangsmaate for aktivering av rekombinante proteiner | |
| ATE413189T1 (de) | Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1 | |
| ATE14226T1 (de) | Cyclische octapeptide und pharmazeutische praeparate davon, sowie verfahren zur herstellung derselben und ihre anwendung. | |
| DK0506748T3 (da) | Aminosyrer, peptider eller derivater deraf bundet til fedtstoffer | |
| DE69315730D1 (de) | Verfahren zur Herstellung von Peptiden und neue Zwischenverbindungen dazu | |
| ATE86260T1 (de) | Peptid-molekuele, wirksam gegen gram-positive keime. | |
| JPS643161A (en) | (2-cyano-2-oxyiminoacetyl)-amino acid derivative | |
| DE59109235D1 (de) | Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung | |
| DE69613086D1 (de) | Antigenen Peptide mit Glycinsubstitution | |
| AU1464488A (en) | Human rhinovirus peptides | |
| EP1870419A3 (de) | Modulatoren der Beta-Amyloid-Peptid-Aggregation mit D-Aminosäuren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0929574 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |